Sida 1 från 61 resultat
So far, no studies have been conducted to evaluate possible correlations between lipid/lipoprotein levels and the anti-phospholipid antibody (aPL) positivity in multiple sclerosis (MS). In this cross-sectional study, we aimed to investigate the relationships between serum lipid profile and aPL
OBJECTIVE
Treatment with beta interferon (IFNbeta) might alter the lipid profile. Plasmatic levels of total cholesterol and low density lipoprotein-cholesterol have been associated with the number of plaques in magnetic resonance of patients with demyelinating syndromes.
METHODS
Retrospective
OBJECTIVE
This study aimed to characterize a population of multiple sclerosis (MS) patients in terms of traditional and new cardiovascular risk factors and assess their putative correlation with clinical disease activity (evaluated by the Expanded Disability Status Scale [EDSS]).
METHODS
Thirty
Experimental autoimmune encephalomyelitis (EAE) is a T-cell-mediated, autoimmune disorder characterized by central nervous system inflammation and demyelination, features reminiscent of the human disease, multiple sclerosis (MS). Prior work in the EAE model has suggested that encephalitogenic T
Altered lipid metabolism is a feature of systemic autoimmune diseases. Dyslipidemia is associated with the disease activity and progression in patients with multiple sclerosis. However, in neuromyelitis optica spectrum disorder (NMOSD), changes in the lipid profile and the associations To investigate associations between lipid profiles and fatigue in a cohort of progressive multiple sclerosis (MS) patients on a diet-based multimodal intervention.This pilot study included 18 progressive MS patients who participated in a prospective OBJECTIVE
Physical activity is strongly recommended as a principal component of coronary heart disease (CHD) risk factor management aimed at favorably lowering abdominal fat accumulation, lowering levels of triglyceride (TG), raising levels of high-density lipoprotein-cholesterol (HDL-C), and
Objective: This study aimed to determine the effectiveness of three different indices used to identify the effect of visceral adiposity on lipid profile markers in patients with multiple sclerosis.
Methods: The study consisted of
We have reported recently that nocturnal melatonin levels are reduced in a subgroup of patients with multiple sclerosis (MS). We have also noted in these patients a high incidence of hypercholesterolemia and propose that this may be linked to dysfunction of the pineal gland since pinealectomy in
Epidemiological findings suggest a relationship between multiple sclerosis (MS) and cardiovascular disease (CVD) risk factors, although the nature of this relationship is not well understood.
We used genome-wide association study (GWAS) data to identify shared genetic factors (pleiotropy) between MS
BACKGROUND
Serum apolipoprotein (apo) A-I was considered to be an immune regulator and could suppress pro-inflammatory cytokines generated by activated T cell in some autoimmune diseases. However, the change of serum apoA-I levels in multiple sclerosis (MS) patients is unknown.
METHODS
In the
A comprehensive clinical and biochemical evaluation has been carried out in patients with multiple sclerosis (MS). Measured in the patients' blood were levels of cholesterol, triglycerides, malonic dialdehyde, and superoxidedysmutase activity. The interrelationship revealed between the above
The authors recently reported the occurrence of low fasting serum triglyceride (TG) and high free fatty acid (FFA) levels in idiopathic pulmonary fibrosis. TG estimation in diverse groups of patients with autoimmune disease or hyperactive immune response confirmed the occurrence of a similar
BACKGROUND
It has been recently suggested that total cholesterol and low density lipoproteins (LDL) levels can behave as biological markers of activity in demyelinating diseases. Thus, our aim has been to describe the modifications of the plasma levels of total cholesterol and triglyceride due to
We have developed a sensitive, ELISA-based assay to detect autoantibodies to myelin basic protein (MBP) in human serum. Autoantibody levels were measured in 98 normal healthy adults (age range 20-66) and 94 clinically definite multiple sclerosis (MS) cases (age range 18-63). Of the MS patients, 77%